Evidence map›Paper›PMID 9250148›Full record

ArticleThe American journal of pathology1997

The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.

S Pittaluga, I Wlodarska, K Pulford, E Campo, S W Morris, H Van den Berghe, C De Wolf-Peeters

Abstract read
In one paragraph

Article in The American journal of pathology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 142 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas.Cold Spring Harbor perspectives in medicine · 2020
    Review
  6. Review
  7. Review
  8. T-cell lymphomas, a challenging disease: types, treatments, and future.International journal of clinical oncology · 2017
    Review
  9. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.Journal of clinical and experimental hematopathology : JCEH · 2017
    Review
  10. Review
  11. Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease.The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique · 2013
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

S PittalugaDepartment of Pathology, University of Leuven, Belgium.
I Wlodarska
K Pulford
E Campo
S W Morris
H Van den Berghe
C De Wolf-Peeters
KU Leuven · BE

Funding

NPM-ALK AND ALK IN LYMPHOMA AND NORMAL DEVELOPMENTR01CA069129 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MORRIS, STEPHAN W · 1996 to 2006
$2.0M
MOLECULAR ANALYSIS OF T(3;5) IN ACUTE MYELOID LEUKEMIAK08CA001702 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MORRIS, STEPHAN W · 1992 to 1996
–
NCI NIH HHS CA01702NCI NIH HHS CA69129
6 · The paper itself

Abstract

Anaplastic large cell lymphoma (ALCL) is a heterogeneous group of diseases by morphology, phenotype, genotype, and clinical presentation. Using a new monoclonal antibody (ALK1) that recognizes the native anaplastic lymphoma kinase (ALK) protein as well as the fusion product of the t(2;5)(p23;q35), nucleophosmin (NPM)/ALK, we investigated for ALK expression cases diagnosed as ALCL as well as lympho-proliferative disorders possessing overlapping features with ALCL. Thirteen cases showed cytoplasmic staining of the neoplastic cells. These cases were characterized by a fairly uniform morphology and occurred in children and young adults as a systemic disease. All other cases comprising T or null ALCL (17 cases), B ALCL (8 cases), Hodgkin's disease (HD) (15 cases), HD-like ALCL (23 cases), and lymphomatoid papulosis (9 cases), were negative for ALK expression. Translocation t(2;5)(p23;q35) was found by classical cytogenetics or interphase fluorescence in situ hybridization in 8 of the ALK1-positive cases and by reverse transcription-polymerase chain reaction in 1 other case. Two additional ALK1-positive cases with an abnormal karyotype, but without t(2;5)(p23;q35), showed by fluorescence in situ hybridization analysis a cryptic NPM/ALK gene fusion caused by an insertion of ALK near NPM in one case and a translocation of ALK to 2q35 as a result of an indiscernible inv(2)(p23q35) in the other. The latter variant translocation points to a localization of an unknown gene at 2q35 that, like NPM, might deregulate ALK and be involved in the pathogenesis of ALCL. In summary, immunohistochemistry with ALK1 antibody allows the identification of a distinct subgroup within the ALCL of T or null phenotype that is associated with 2p23 abnormalities and lacks the marked histological pleomorphism described in ALCL in general. Whereas immunostaining is the most sensitive method to identify this group, it does not help to additionally clarify the relationship among ALCL, HD, and HD-like ALCL.

Indexed as

Chromosomes, Human, Pair 2Chromosomes, Human, Pair 5AdolescentAdultAgedAnaplastic Lymphoma KinaseAntibodies, MonoclonalAntibodies, NeoplasmChildFemaleGene Rearrangement, T-LymphocyteHumansIn Situ Hybridization, FluorescenceLymphoma, Large B-Cell, DiffuseMaleMiddle AgedALK protein, humanAnaplastic Lymphoma KinaseAntibodies, MonoclonalAntibodies, NeoplasmProtein-Tyrosine KinasesReceptor Protein-Tyrosine Kinases

Identifiers

PMID9250148
PMCPMC1858018
OpenAlexW56943605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.